About BioLife Solutions (NASDAQ:BLFS)
BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; and contract aseptic manufacturing formulation, filling, and finishing services for liquid media products. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly using its sales force, as well as through biolifesolutions.com; and through various regional distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Industry Electromedical equipment
Trailing P/E Ratio-61.29
Forward P/E Ratio-429.00
Sales & Book Value
Annual Sales$11.02 million
Price / Sales16.53
Price / CashN/A
Book Value$0.72 per share
Price / Book17.88
EPS (Most Recent Fiscal Year)($0.21)
Return on Equity-18.99%
Return on Assets-15.72%
BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions
What is BioLife Solutions' stock symbol?
BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."
How were BioLife Solutions' earnings last quarter?
BioLife Solutions Inc (NASDAQ:BLFS) posted its quarterly earnings data on Thursday, March, 8th. The medical equipment provider reported ($0.05) EPS for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.02. The medical equipment provider earned $3.13 million during the quarter, compared to the consensus estimate of $3.10 million. BioLife Solutions had a negative return on equity of 18.99% and a negative net margin of 13.17%. View BioLife Solutions' Earnings History.
When is BioLife Solutions' next earnings date?
What price target have analysts set for BLFS?
4 analysts have issued 1-year price targets for BioLife Solutions' stock. Their predictions range from $5.00 to $14.00. On average, they expect BioLife Solutions' stock price to reach $10.3333 in the next twelve months. View Analyst Ratings for BioLife Solutions.
Who are some of BioLife Solutions' key competitors?
Some companies that are related to BioLife Solutions include Cutera (CUTR), Viewray (VRAY), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Fonar (FONR), Second Sight Medical Products (EYES), Viveve Medical (VIVE), Zynex Inc. common stock (ZYXI), Edap Tms (EDAP), Semler Scientific (SMLR), IRIDEX (IRIX), BioSig Technologies (BSGM), Soleno Therapeutics (SLNO) and Stereotaxis (STXS).
Who are BioLife Solutions' key executives?
BioLife Solutions' management team includes the folowing people:
- Mr. Michael P. Rice, Pres, CEO & Director (Age 55)
- Mr. Roderick de Greef, CFO & Sec. (Age 58)
- Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Chief Technology Officer and Sr. VP (Age 46)
- Ms. Karen Foster, VP of Operations (Age 58)
- Mr. Kevin O'Donnell, VP of Cold Chain Standards, Practices & Compliance
Has BioLife Solutions been receiving favorable news coverage?
Media headlines about BLFS stock have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioLife Solutions earned a media sentiment score of 0.10 on Accern's scale. They also assigned news headlines about the medical equipment provider an impact score of 46.61 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are BioLife Solutions' major shareholders?
BioLife Solutions' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include GIRSCHWEILER THOMAS (21.60%), CASDIN CAPITAL, LLC (7.10%), Millennium Management LLC (1.71%) and Granite Investment Partners LLC (0.79%). Company insiders that own BioLife Solutions stock include Andrew G Hinson, Greef Roderick De, Joseph C Schick, Michael Rice, Raymond W Cohen and Thomas Girschweiler. View Institutional Ownership Trends for BioLife Solutions.
Which major investors are selling BioLife Solutions stock?
BLFS stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC. Company insiders that have sold BioLife Solutions company stock in the last year include Andrew G Hinson, Greef Roderick De, Joseph C Schick, Michael Rice, Raymond W Cohen and Thomas Girschweiler. View Insider Buying and Selling for BioLife Solutions.
Which major investors are buying BioLife Solutions stock?
How do I buy shares of BioLife Solutions?
Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioLife Solutions' stock price today?
One share of BLFS stock can currently be purchased for approximately $12.87.
How big of a company is BioLife Solutions?
BioLife Solutions has a market capitalization of $182.05 million and generates $11.02 million in revenue each year. The medical equipment provider earns $-2,510,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. BioLife Solutions employs 40 workers across the globe.
How can I contact BioLife Solutions?
BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]
MarketBeat Community Rating for BioLife Solutions (BLFS)MarketBeat's community ratings are surveys of what our community members think about BioLife Solutions and other stocks. Vote "Outperform" if you believe BLFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLFS will underperform the S&P 500 over the long term. You may vote once every thirty days.